Abstract 1203P
Background
Acute myeloid leukemia (AML) is the most common leukemia in adults and current methods rely on cytogenic and molecular profiling for AML classification. Recent advances have demonstrated that next generation sequencing (NGS) may improve prognostic prediction and risk stratification of AML patients. A tumour-only high coverage whole genome sequencing (WGS) method was developed to assess the analytical performance (limit of detection (LoD)), sensitivity, specificity and reproducibility) in identifying somatic small variants, structural variants (SV) and copy number alterations (CNA) specific to AML.
Methods
Seracare® myeloid panel, NOMO1, Kasumi1, HCC1187 and 53 AML clinical specimens were used to assess analytical performance. Extracted genomic DNA (∼350ng) from contrived specimens, cell lines, mononuclear cells from whole blood or bone marrow aspirate were manually processed with Illumina DNA PCR Free Prep and sequenced at 4 plex on S4 flowcells using NovaSeq™ 6000. The sequence data was analysed by DRAGEN™ Somatic v4.2 with a custom virtual 156 AML specific gene panel variant classification algorithm.
Results
The samples were sequenced at an average of ∼220X which yielded high analytical sensitivity, accuracy and reproducibility of the specimens evaluated in this study. Although the target sequence was ∼220X, samples were in silico down sampled to 140X to establish the following performance specifications. LoD was established for small variant (SNVs and indels) and SV to be 5% and 7.3%, respectively. CNA were detected with copy number fold change of 1.09 and 0.87 for duplication and deletion events, respectively. Further, loss of heterozygosity was detected with purity of 17%. Overall, we observed accuracy >95% across clinical samples with analytical sensitivities >95%, >99% and >95% for small variants, SV and CNA, respectively and analytical specificity of >99.9%.
Conclusions
We have developed a tumour only WGS method for genomic profiling of AML patients with a turn around time of 5 days. The analytical performance of this tumour only WGS approach indicates high accuracy in identifying variants indicative for AML. In addition, the high sequence depth provides improved analytical sensitivity compared to other genome sequencing or cytogenetic methods.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Illumina.
Funding
Illumina.
Disclosure
G. Malagoli Tagliazucchi, W. Gong, M. Ghildiyal, M. Chavez, K. Nobuta, E. Sayyari, S. Truong, T. Vang, G. Kim, Q. Bui, S. Kim, J. Bernd, E. De Feo, S. Comer: Financial Interests, Institutional, Full or part-time Employment: Illumina. M. Yaylaoglu: Financial Interests, Personal and Institutional, Full or part-time Employment: Illumina. D. Spencer: Financial Interests, Institutional, Financially compensated role: Washington University in St. Louis.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10